BUZZ-Revolution jumps after US FDA adds its drug under new fast-track process

Reuters
10/17
BUZZ-Revolution jumps after US FDA adds its drug under new fast-track process

** Shares of drug developer Revolution Medicines RVMD.O up 7.7% to $53.51 premarket

** U.S. FDA announced nine products, including RVMD's daraxonrasib for pancreatic cancer, under new fast-track review process

** Selected drugs could get approval within one to two months of filing a complete application; typical review time is 10 to 12 months

** Brokerage Oppenheimer thinks daraxonrasib's first approval could come as early as mid-2026

** Eli Lilly's LLY.N experimental weight-loss pill, orforglipron, was expected to be included in the list

** Separately, Trump signaled the price of LLY's Danish rival Novo Nordisk's weight-loss drug would be lowered

** LLY shares down 4.2% premarket

** YTD, up to last close, RVMD up 13.6% vs LLY's 6.1% rise

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10